Om

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalised cancer medicines, including targeted therapies and cell therapies. The company’s current portfolio centres on investigational programs for haematological and solid cancers, with a particular emphasis on blood cancers and difficult-to-treat oncology indications. Its lead assets include PTX-100, a targeted therapy in clinical development, alongside OmniCAR and CellPryme, two cell therapy platform technologies designed to improve the performance and flexibility of next-generation CAR-T and adoptive cell therapies. Prescient Therapeutics works across drug discovery, clinical development, and platform-based innovation, leveraging research collaborations with leading academic and medical centres. The company plays a niche role in the biotechnology market by advancing experimental oncology treatments that aim to address unmet medical needs through precision medicine approaches.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I PRESCIENT THERAPEUTICS MED ENDAVU: Køb Prescient Therapeutics ($UDD) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Prescient Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.